Haleon plc revenue

Haleon plc's revenue was $14.55bn in fiscal 2025, up 1.3% on the year before. Since fiscal 2020 ($12.69bn) it has grown at a compound 2.8% a year.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Haleon plc: revenue history, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	12.7	13.1	13.4	14.1	14.4	14.6
Growth on the year before	—	+3.5%	+2.2%	+4.7%	+2.1%	+1.3%
Gross profit	7.6	8.2	8.1	8.4	8.7	9.3
Gross margin	59.7%	62.3%	60.6%	59.7%	60.7%	64.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Haleon plc	$14.55bn	1.3%	—
Viatris	$14.74bn	4.4%	-1.9%
Universe Pharmaceuticals Inc	$17.86bn	-22.4%	—
Bausch Health Companies Inc.	$11.11bn	10.8%	9.2%
Zoetis	$9.52bn	1.5%	5.0%
Organon & Co.	$6.10bn	-3.2%	-0.3%

Compare with peers

Head to head: HLN vs VTRS HLN vs UPC BHC vs HLN HLN vs ZTS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Haleon plc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Haleon plc.